Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Investors pinned hopes on Nvidia Corp.’s (NASDAQ:NVDA) earnings to reinvigorate market momentum, and the AI leader delivered an impressive ...
Moderna, Inc. (NASDAQ: MRNA) is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 22, 2024. Analysts exp...
Moderna Inc (NASDAQ:MRNA) shares are trading lower after a longer-term trial analysis revealed a faster decline in the effectiveness of its ex...
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-...
Pharmaceutical companies await the U.S. government’s forthcoming proposal, expected this Thursday, outlining substantial discounts for t...
The Nasdaq 100 closed lower by over 90 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. "I think that Stepha...
Oxford Vaccine Group, part of the University’s Pandemic Sciences Institute, has commenced the first-in-human trial of the ChAd...
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefin...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...